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Abstract
Background: Development of a cancerous cell takes place when it ceases to respond to growth-inhibiting signals
and multiplies uncontrollably and can detach and move to other parts of the body; the process called as
metastasis. A particular set of cysteine proteases are very active during cancer metastasis, Cathepsins being one of
them. They are involved in tumor growth and malignancy and have also been reported to be overexpressed in
tumor cell lines. In the present study, a combinatorial approach comprising three-dimensional quantitative
structure-activity relationship (3D QSAR), ligand-based pharmacophore modelling and search followed by cathepsin
L structure-based high throughput screening was carried out using an initial set of 28 congeneric
thiosemicarbazone derivatives as cathepsin L inhibitors. A 3D QSAR was derived using the alignment of a common
thiosemicarbazone substructure. Essential structural features responsible for biological activity were taken into
account for development of a pharmacophore model based on 29 congeneric thiosemicarbazone derivatives. This
model was used to carry out an exhaustive search on a large dataset of natural compounds. A further cathepsin L
structure-based screen identified two top scoring compounds as potent anti-cancer leads.
Results: The generated 3D QSAR model showed statistically significant results with an r2 value of 0.8267, cross-validated
correlation coefficient q2 of 0.7232, and a pred_r2 (r2 value for test set) of 0.7460. Apart from these, a high F test value of
30.2078 suggested low probability of the model’s failure. The pharmacophoric hypothesis chosen for searching the natural
compound libraries was identified as DDHRR, where two Ds denote 2 hydrogen donors, H represents a hydrophobic
group and two Rs represent aromatic rings, all of which are essential for the biological activity. We report two potential
drug leads ZINC08764437 (NFP) and ZINC03846634 (APQ) obtained after a combined approach of pharmacophore-based
search and structure-based virtual screen. These two compounds displayed extra precision docking scores of -7.972908
and -7.575686 respectively suggesting considerable binding affinity for cathepsin L. High activity values of 5.72 and 5.75
predicted using the 3D QSAR model further substantiated the inhibitory potential of these identified leads.
Conclusion: The present study attempts to correlate the structural features of thiosemicarbazone group with their
biological activity by development of a robust 3D QSAR model. Being statistically valid, this model provides near
accurate values of the activities predicted for the congeneric set on which it is based. These predicted activities are
good for the test set compounds making it indeed a statistically sound 3D QSAR model. The identified pharmacophore
model DDHRR.8 comprised of all the essential features required to interact with the catalytic triad of cathepsin L.
A search for natural compounds based on this pharmacophore followed by docking studies further screened out two
top scoring candidates: NFP and AFQ. The high binding affinity and presence of essential structural features in these
two compounds make them ideal for consideration as natural anti-tumoral agents. Activity prediction using 3D QSAR
model further validated their potential as worthy drug candidates against cathepsin L for treatment of cancer.
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Background
Cancer is a condition characterized by unregulated growth
and division of cells that have become abnormal and can
invade adjoining parts of the body. Cancerous cells arise as
a consequence of mutations in the critical genes. Accord-
ing to the world cancer report, an estimated number of
7.6 million fatalities were recorded in 2008 and 12.7 million
new cases were diagnosed. This number is expected to rise
to 21 million by 2030 [1]. A series of proteolytic enzymes
are a pre-requisite for the tumor cells to undergo metasta-
sis in which tumor cells travel to distant organs and form
new tumors [2-6]. Cysteine proteases are a group of such
proteolytic enzymes that are characterized by a cysteine
residue in their active site region [7-13]. Cathepsins are a
subfamily of 11 human lysosomal cysteine proteases
included in the papain family [14]. Most of them have been
found to be involved in tumor growth and malignancy.
Cathepsin L is a globular endopeptidase which plays an
important role in vital physiological processes and is
reported to be overexpressed in various human tumors
[15-17]. Knowledge of this family of proteases and their
inhibitors can prove to be a major breakthrough in cancer
management and thus is the subject of interest for the pre-
sent study [18]. Various inhibitors have been characterized
and studied extensively against cathepsins, for e.g. nitriles
[19], azepanone analogues [20] and disulfides [21] among
others. In the present study we focus on the thiosemicarba-
zone moiety that has been utilized previously in the devel-
opment of anticancer agents by inhibition of cathepsin L.
Thiosemicarbazones incorporate an important class of
N, S-donor ligands [22], and are basically schiff bases
obtained by condensation of thiosemicarbazides with an
aldehyde or ketone [23]. They first appeared in the 50’s
as drugs against tuberculosis and leprosy [24,25]. Later,
their antiviral properties were reported which led to a
huge research in this area resulting in commercialization
of methisazone also named as Marboran, to treat small-
pox [26]. Benzophenone thiosemicarbazone derivatives
have earlier been reported as potential therapeutics
against malaria, sleeping sickness and chagas’ disease
[27-30]. Recently, antitumor activity of KGP94, a func-
tionalized benzophenone thiosemicarbazone derivative,
was evaluated for breast cancer against cathepsin L [31].
Triapine (3-aminopyridine-2-carboxaldehyde thiosemi-
carbazone) has already been evaluated as ribonucleotide
reductase inhibitor for anticancer therapy [32]. Apart
from these, various other derivatives of thiosemicarba-
zones such as thiophene, pyridine and fluorene have
also been tested as inhibitors of cathepsin L and their
IC50 values have been reported [33,34].
A fast and accurate approach to search for novel thera-
peutics against various cancers is the need of the hour.
In silico methods involving ligand based drug design are
viable approaches to speed up the drug discovery process.
3D QSAR has emerged as a robust technique in rational
drug design to predict the biological activities of the
prospective inhibitors using the knowledge of three-
dimensional properties of the ligands through a chemo-
metric approach. It develops statistically significant
models to guide synthesis of novel inhibitors on the
assumption that the extent of receptor binding directly
relates to its biological activity [35,36]. In 3D QSAR,
molecular structures are represented by a set of numbers
called as descriptors. For QSAR model development, the
receptor binding site is considered to be rigid and the
ligand molecules should belong to a congeneric series
[37]. From a pool of molecular descriptors, optimal vari-
ables are chosen using a stochastic method. Molecular
fields, which are basically steric and electrostatic interac-
tion energies, are calculated and a molecular field analysis
model is predicted [38]. The model thus generated is
evaluated for its robustness by determining its capacity to
predict the activity of compounds not belonging to the
training set. This validation is done based on the calcula-
tion of statistical parameters. On the other hand, a phar-
macophore is a molecular framework that carries the
essential features responsible for a drug’s biological
response [39]. Features like aromatic rings, hydrogen
donors and acceptors, hydrophobes and positively and
negatively ionisable chemical groups are marked and the
resulting pharmacophoric hypothesis is scored for its
validity. Natural compounds in good alignment with such
a hypothesis can be taken as potent drug leads.
In this study, a congeneric dataset comprising of 28
thiosemicarbazone derivatives was first chosen to build a
3D QSAR model that evaluates the activity of the ligands
against cathepsin L. And we also find out the molecular
features essential for their activity using the pharmaco-
phore model. Despite the continuous efforts in the direc-
tion of finding novel cathepsin L inhibitors, there are no
clinical agents available in human clinical trials yet [31].
This study establishes the use of thiosemicarbazone deri-
vatives by contributing towards understanding its essen-
tial characteristics as potent anti-cancer candidate and
thus paves way for an accelerated evaluation of novel
thiosemicarbazone-based lead candidates using the pre-
dicted QSAR model.
Materials and methods
Compound dataset for model development
In this study, a congeneric series of thiosemicarbazone
derivatives with inhibitory properties against human cathe-
psin L were selected for 3D-QSAR model development
[33,34]. The 2D structures of the template molecule and
61 derivatives were drawn using Chemsketch [40] which
were then aligned with the most active molecule (refer-
ence molecule). A total of 28 molecules were selected on
alignment with the thiosemicarbazone template based on
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lower RMSD values, which indicate optimal alignment.
These 2D structures were converted to 3D using Vlife
Engine platform of VLifeMDS [41] and later energy mini-
mized using the force field batch minimization utility with
default parameters. These optimized compounds were
finally used for 3D-QSAR model development.
Computation of force field
The 28 aligned compounds along with their pIC50 values
were given as input for force field calculation. For 3D
QSAR, a force field was computed keeping default grid
dimensions and including steric, electrostatic and hydro-
phobic descriptors while keeping dielectric constant at the
default value (1.0). The charge type chosen for computa-
tion was Gasteiger-Marsili. The values calculated for the
descriptors along with their grid points were arrayed upon
the worksheet and the invariable columns were removed
using QSAR tools.
Model development
Using advanced data selection wizard, the column con-
taining the activity values (pIC50) of the compounds was
selected as the dependent variable and the rest as inde-
pendent variables. After manual selection of the test set,
the unicolumn statistics of both the test and the training
sets were calculated. This analysis provided validation of
the chosen training and test sets. A critical step in QSAR
model development is the selection of optimal variables
from the available set of descriptors which set out a sta-
tistically significant correlation of the structure of com-
pounds with their biological activity. Using the variable
selection and model building wizard, the model was built
by stepwise-forward method [42]. All the values were
kept default except the number of descriptors in the final
equation which was changed to 4 and variance cut-off as
0.1. This variable selection method can be combined with
a number of different regression analysis techniques like
partial least squares (PLS) [43], partial component regres-
sion [44], k nearest neighbour [45] among others by
selecting the appropriate combination. In the present
study, we report a 3D QSAR model built using PLS.
Model validation
Many statistical parameters like n (number of com-
pounds in regression), k (number of variables), degree of
freedom, optimum component (number of optimum PLS
components in the model), r2 (squared correlation coeffi-
cient), F-test (Fischer’s value), q2 (cross-validated correla-
tion coefficient), pred_r2 (r2 for external test set), Z score
(randomisation test), best_ran_q2 (highest q2 value in the
randomisation test) and best_ran_r2 (highest r2 value in
the randomisation test) need to be taken into account to
consider the model as a robust one. For a model to be
statistically significant, the following conditions should
be considered: r2, q2 > 0.6 and pred_r2 > 0.5 [1,2]. Since,
F-test gives an idea of the chances of failure of the model,
a value greater than 30 is considered to be good. On the
other hand, low standard error values establish absolute
quality of the model.
Internal and external validation
For internal validation using leave-one-out method [46],
the cross-validated coefficient, q2 is calculated using the
given equation:








where yi and yˆi are the actual and predicted activities
of the ith molecule (i = 1-24 except 9: refer Additional
file 1) in the training set, respectively, and ymean is the
average activity of all the molecules in the training set.
For external validation, the pred_r2 value that gives an
account of the statistical correlation between predicted
and actual activities of the test set compounds was cal-
culated as follows:








where yi and yˆi are the actual and predicted activities
of the ith molecule (i = 25-29: refer Additional file 1) in
the test set, respectively, and ymean is the average activity
of all the molecules in the training set.
To avoid the risk of chance correlation, Y randomisa-
tion test was carried out by comparing the resultant lin-
ear model with those derived from random data sets.
Various models were built on random datasets gener-
ated by rearranging the molecules in the training set so
as to compare them with the obtained 3D QSAR model
on the basis of Z-score [47]. A Z-score value is calcu-




where h is the q2 value calculated for the actual data
set, μ is the average q2 and σ is the standard deviation
calculated for various models built on different random
data sets.
Pharmacophore-based virtual screening
Using the same set of compounds as taken for the 3D
QSAR model development, we embarked upon a search
for similar anti-cancer natural compounds. The essential
features responsible for a molecule’s biological activity
are represented through a pharmacophoric hypothesis,
which is then used for a rigorous search for compounds
constituting the same features. The pharmacophore
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model was created using the Phase module of Schrodin-
ger [48]. It is a 5-step procedure which is carried out by
selecting the 3D optimized molecules, prepared using
Ligprep and manually entering their activity values
(pIC50). A number of hypotheses were generated along
with their respective set of aligned conformations. Using
Phase, an exhaustive search was done for a lead mole-
cule based on the pharmacophore after selecting the
best hypothesis amongst them.
Virtual screening targeted against cathepsin L
The compounds screened after pharmacophore-based
search were further evaluated for their inhibitory potency
against Cathepsin L by using Schrodinger’s Glide docking
platform [49,50]. It works by creating a cubic grid (10 A˙
side) around the user-specified critical residues and
directing the approaching ligand at the specific site. An
extra precision (XP) docking was carried out to screen
7409 compounds obtained after pharmacophore based
screening, of which those lying above the specified
threshold were chosen. XP docking serves the purpose of




A 3D-QSAR model development works to find a statisti-
cal correlation between the structures and activity of
chemical compounds by calculating 3D molecular
descriptors which include steric, electrostatic and hydro-
phobic points marked on the 3D spatial grid. After
selecting the Gasteiger-Marsili charges for computing
the force field grid, the invariable columns were
removed which reduced the descriptor number from
2971 to 2944. pIC50 was selected as the dependent vari-
able while the calculated 3D descriptors were chosen as
independent variables. The test set constituting the
compounds A3, A5, A9, A19 and A34 (Additional file 1)
was selected manually after which the unicolumn statis-
tics were calculated for both the training and test set
compounds.
Unicolumn statistics
The unicolumn statistics analysis showed that the train-
ing and test sets were suitable for 3D-QSAR model
development. For an appropriate model, max of the
training set should be more than max of the test set and
min of the test set should be higher than min of the
training set. The unicolumn statistics scores are shown
in Table 1. The max and min of the training and test
sets were found in concurrence with the ranges specified
and suggested that the test set was interpolative. Besides,
the relative difference between the mean and point den-
sity distribution of the two sets was determined by the
mean and standard deviation. In this case, the mean of the
test set was a bit lower than the train set implying the pre-
sence of relatively moderate number of active molecules as
compared to the inactive ones. Also, the similarity in stan-
dard deviation indicated that the spread with their respec-
tive means in both the sets were comparable.
Linear model equation and validation with statistical
parameters
Selecting the stepwise forward (SW) variable selection
method, we built a 3D-QSAR model for which the details
are given. The selected descriptors were E_86, E_943,
E_463, and S_482, which represent steric and electrostatic
field energy of interactions at their respective spatial grid
points. No hydrophobic descriptor was found contributing
in the final model obtained by the SW algorithm. The
numbers in the chosen descriptors represented their posi-
tions on the 3D spatial grid. Equation 1 represents the
obtained 3D QSAR model:
pIC50 = 3.89857 (E 86)+3.12363 (E 943)−0.114297 (E 463)+0.0152502 (S 482)+5.73211 (1)
While each descriptor is accompanied by a numerical
coefficient, the last single numerical value is the regression
coefficient. This model was both internally and externally
validated using the LOO method by calculating statistical
parameters which are critical requirements for a model to
be robust. The number of compounds in the training set
was specified by N which is 23 in this case. Considering
the correlation coefficient, r2 (0.8267), cross-validated cor-
relation coefficient q2 (0.7232), pred_r2 (0.7460), low stan-
dard error value, r2_se (0.3194), q2_se (0.4036) and
pred_r2_se (0.3619), the model can be stated to be a robust
one. Along with this, the F-test value (30.2078) implied
that the model is 99 % statistically valid with 1 in 10000
chance of failure. Other important statistical parameters
are presented in Table 2. Z-scores for r2, q2 and pred_r2
have been specified to emphasize its importance in QSAR
model validation. Zscore_r2 of 5.55599 implies a 100%
area under the normal curve. Zscore_q2 of 3.71813 implies
a 99.99% area under the normal curve and Zscore_pred_r2
of 1.45442 implies a 92.70% area under the normal curve
all of them indicating that the respective scores are not far
away from the mean ‘μ’ and thus validate the model’s sta-
tistical robustness.
The robustness of the model is better understood
through the linear graphical representation between
actual and predicted activities of the final 28 compounds
Table 1 Unicolumn statistics for training and test set for
Cathepsin L inhibiting compounds
Set Column name Average Max Min Std Dev Sum
Training pIC50 6.5100 7.6400 5.310 0.7130 14.7297
Test pIC50 6.3022 7.0990 5.580 0.6795 3.5110
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(Figure 1) and radar plots for training and test sets
(Figure 2 (a, b)). The linear graphical representation
shows the extent of variation between the actual and
predicted activities of the congeneric set. The larger the
distance of training and test set points from the regres-
sion line, more is the difference between the actual and
the predicted activity values. The radar graphs depict
the difference in the actual and predicted activities for
the training and the test sets separately by the extent of
overlap between blue (actual activity) and red (predicted
activity) lines. The radar plot for training set represents
a good r2 value if the two lines show a good overlap
while for the test set a good overlap represents high
pred_r2 value. The contribution plot for each descriptor
is given in Figure 3. The contribution of each descriptor
specifies the properties that should be present in the
drug lead for its enhanced inhibitory activity. Presence
of descriptors with positive contribution increases its
inhibitory activity while descriptors with negative contri-
bution decrease the same. For electrostatic descriptors, a
positive contribution indicates the requirement of elec-
tropositive group at that site and an electronegative
group for negatively contributing descriptor.
The grid points E_86, E_943 and S_482 had a positive
contribution (38.318%, 28.499% and 9.023% respectively)
towards the activity of thiosemicarbazones against cathe-
psin L, while the descriptor E_463 contributed negatively.
Steric descriptors are related to both the size and shape
of the molecules and fragments and all the bulk descrip-
tors can be regarded as steric descriptors. A positively
contributing steric descriptor signifies the importance of
the presence of a bulky group at that position. As can be
seen in the grid box (Figure 4), S_482 owing to its proxi-
mity to the bulky benzophenone moiety in the cubic grid
suggests its importance at that site as activity enhancer.
Electrostatic descriptors describe the importance of the
presence of electronegative and electropositive groups at
a site. Positively contributing electrostatic descriptors sig-
nify the importance of electropositive groups and nega-
tively contributing ones signify the importance of
electronegative groups. E_86 and E_943, both having
positive contribution, lie relatively far away from the elec-
tronic cloud of the molecule. The presence of electrone-
gative groups at R1 benzophenone site is therefore a
necessity given the electropositivity enhancing descrip-
tors lying far away. The third electrostatic descriptor
E_463 contributes negatively and therefore acknowledges
the presence of a highly electronegative group like halo-
gens, O or N at the R1 benzophenone site for activity
enhancement. Thus the R1 aromatic ring must have elec-
tronegative groups attached in order to increase the
activity, for which compounds A1 and A19 are good
examples having a highly electronegative fluorine atom
attached at the 2nd position. Compounds A7 and A18
with bulkier electronegative substituent at the 3rd posi-
tion are few other examples.





















pIC50 5.55599 3.71813 0.56529 0.32339 0.0000 0.00100 1.45442 0.90479 0.100000
Figure 1 Graphical representation of observed vs. predicted activity for training and test set.
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Pharmacophore model
Pharmacophore development from a given set of mole-
cules with high inhibitory activity against a particular
protein target is a highly viable approach in ligand based
drug design. It is done by using fine-grained conforma-
tional sampling and an array of scoring techniques to
identify highly potent therapeutics. A pharmacophore
conveys minimal characteristics of the structures of the
Figure 2 Radar plots showing the observed and predicted activities for (a) training set (b) test set.
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ligands which are critical for binding to the target. Each
hypothesis is accompanied with a set of aligned confor-
mations that suggest the mode in which molecules are
likely to bind relatively [48]. After selecting the maxi-
mum number of sites to be 5 (each site is involved in a
2-3 Kcal/mol interaction with the receptor), alignments
were generated using model ligands that are a part of the
active set of the series. The compounds A30, A35 and
B14 (refer Additional file 1) were not selected out of total
29 (Additional file 1) for alignment thus reducing the
number of matches to 26 for all the hypotheses. The
hypotheses obtained along with their survival scores and
selectivity are reported in Table 3.
Scoring function
In order to assign a score, each pharmacophore along
with its ligand are temporarily regarded as the reference
and other non-reference pharmacophores are aligned
one by one using a least square procedure. Further a site
score, a vector score and a volume score are calculated
Figure 3 Contribution plot of 3D descriptors of the generated QSAR model.
Figure 4 Depiction of aligned congeneric set of molecules and 3D descriptors marked in the cubic grid.
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with combined weights for each aligned pharmacophore.
Pharmacophoric hypotheses were scored on the basis of
how good the alignment exists between the active set
molecules and pharmacophoric features. After choosing
the hypothesis for each box, the final scoring is done and
the resultant is called the survival score of a hypothesis
that characterizes its validity and potential to be used for
a given set of molecules. The survival score constitutes a
number of various scores and weights calculated during
hypothesis generation as presented in equation 2.
S = WsiteSsite +WvecSvec +WvolSvol +WselSsel +Wmrev −WE E +Wact A (2)
where W’s are the weights and S’s are the scores
We selected a common pharmacophore hypothesis
comprising of common chemical features of the aligned
active molecules from the congeneric set. The final
hypothesis, DDHRR.8 was chosen based on high selectivity
as well as the survival score which yields the best align-
ment of the active set ligands. Along with the site score
(0.318008), vector score (0.908012) and volume score
(0.581835) DDHRR.8 was the best choice for searching a
compound library.
Clearly, the name DDHRR implies the presence of two
hydrogen donors, one hydrophobic group and two aro-
matic rings. In Figure 5 the hydrogen donors are marked
with light blue spheres centered on the H atom with the
arrows directing towards potential H-bonds and the aro-
matic rings marked as group sites represented by orange
torus (ring), located at the centroid of a group of atoms.
These marked sites give an idea about the mode of inter-
action of a lead molecule with Cathepsin L. As repre-
sented in Figure 5(a), an alignment of the 26 compounds
from the congeneric series with that of the chosen
hypothesis, DDHRR.8, supported its selection as the
common pharmacophore hypothesis. In Figure 5(b),
intersite distances (distances between pharmacophore
site pairs) have been shown. Similar hypotheses were
grouped together according to their intersite distances to
identify the common pharmacophore.
Pharmacophore based screening to identify anti-cancer
leads
On screening the compound library based on the phara-
macophoric hypothesis DDHRR.8, the resulting 7409
compounds were subjected to XP docking against cathe-
psin L (PDB ID 2YJ2) http://www.rcsb.org. The resultant
6 compounds that scored above the threshold were
selected. The 3D-QSAR model developed using the
same congeneric series as that of the pharamacophoric
model was used to predict the activity of the resultant 6
compounds. The docking scores and predicted activities
are summarised in Table 4. We report the top two scor-
ing compounds obtained and evaluated through this
combined approach.
The XP score gives the extent of binding affinity of the
respective lead molecules with Cathepsin L, all of them
lying under the specified threshold. We focused on the
catalytic triad comprising of residues Cys25, Met161 and
Asp162 and analyzed the interactions taking place
between Cathepsin L and the thiosemicarbazone series
(Figure 6). The first compound reported [N-(2-(1H-imi-
dazol-4-yl) ethyl)-3-(3,5-dimethyl-7-oxo-7H-furol[3,2-g]
chromen-6-yl)propanamide] (NFP, ZINC08764437) is a
bulky ringed structure that interacted with the catalytic
triad along with other residues: Ala138, Gly139, Trp26,
Gly68, Ala135, Gly164, Leu69, and Ala214 (Figure 7A).
The next top scoring candidate [3-[3-(4-aminophenyl)
amino-3-(2-hydroxy-1-naphthyl)-propanoyl]-4-hydroxy-1-
methyl-quinolin-2-one] (APQ, ZINC03846634), again a
bulkier one, weakly interacted with the catalytic triad
apart from Gly67, Gly68, Leu69, Met70, His163, Ala135
and Ala214 (Figure 7B). It can be inferred that due to the
Table 3 Statistical values of all the pharmacophore hypotheses generated for virtual screening
Row ID Survival Survival-inactive Selectivity Matches
1 ADDRR.4 3.691 1.131 1.526 26
2 ADDRR.8 3.693 1.130 1.548 26
3 ADDHR.6 2.588 0.843 1.649 26
4 ADDHR.12 2.997 0.843 1.668 26
5 ADDHR.18 2.956 0.819 1.687 26
6 ADDHR.15 2.809 0.737 1.731 26
7 ADDHR.16 2.748 0.747 1.737 26
8 ADDHR.20 2.708 0.706 1.745 26
9 ADHRR.4 2.812 0.780 1.781 26
10 ADHRR.6 2.796 0.755 1.837 26
11 ADHRR.10 2.781 0.743 1.865 26
12 DDHRR.8 2.808 0.756 2.058 26
13 DDHRR.12 2.792 0.741 2.068 26
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steric hindrance caused by its bulky aromatic groups,
APQ fails to interact closely with Cys25, Met161 and
Asp162. The align score refers to the extent of similarity
with the chosen hypothesis, DDHRR.8. Align score was
found to be highest for NFP being 1.195091 while for
APQ it was 0.974276. We predicted the activities of the
top scoring compounds using the generated 3D-QSAR
model. The high predicted activities of NFP (5.72) and
Table 4 Top scoring compounds screened using the selected pharmacophore hypothesis
Compound ID XP score Align Score Vector Score Volume Score Fitness Predicted activity (using 3D QSAR model)
ZINC08764437 -7.972908 1.195091 0.567087 0.348039 0.919217 5.729
ZINC03846634 -7.575686 0.974276 0.229897 0.310700 0.728700 5.750
ZINC03846477 -7.222795 0.996626 0.614281 0.438287 1.222046 5.701
ZINC35415799 -7.173709 0.887849 0.369075 0.334232 0.963432 5.760
ZINC13570446 -7.071575 0.961697 0.405166 0.327059 0.930810 5.7553
ZINC13570446 (conformer) -7.054554 0.628301 0.303334 0.325527 1.105277 5.790
Figure 5 Alignment of dataset molecules along with pharmacophoric features of DDHRR.8.
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Figure 6 Chemical structures of screened natural molecules (a) NFP (b) APQ.
Figure 7 Hydrophobic interactions between cathepsin L and screened compounds (a) NFP (b) APQ.
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APQ (5.75) suggested that it is worth to consider them
potent cathepsin L inhibitors.
Conclusion
We used a combined approach to screen potent cathepsin
L inhibitors that promised to emerge as important leads in
cancer research owing to the role that cathepsin L plays
during tumor development and metastasis. A congeneric
set belonging to the thiosemicarbazone class of molecules
which are known to inhibit human cathepsin L was cho-
sen to build a 3D-QSAR model and a pharmacophore
model. The former related the structure of the molecule
with its activity quantitatively while validating the relation-
ship using statistical parameters whereas the later pointed
out the minimal structural features critical for a molecule
for its biological activity and also provided an insight into
the mode of binding with the target. Using these two
approaches of ligand based drug designing we screened a
chemical library based on the pharamacophoric hypothesis
and then predicted their activity using the 3D QSAR
model. The compounds obtained after pharmacophore-
based search were docked at the active site (catalytic triad)
of cathepsin L to further substantiate its role as a cathe-
psin L inhibitor. The two top scoring compounds NFP
and APQ show good binding affinity with cathepsin L.
This study presents a comprehensive view of the correla-
tion between the structure and activity of these molecules
along with their mode of binding with the target protein.
This study progresses the use of thiosemicarbazone moiety
as anti-tumoral and suggests further investigation into the
role of human cathepsin L in the propagation of metasta-
sis. Results of this study will also guide the design of
potent anti-tumorals based on cathepsin L inhibition to
further strengthen already available drug batch against
cancer.
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